name one example of an Australian biotech where listing in the US has been positive for investors. Either dual listing or delisting on asx and re-listing.
IMO Hashan won’t allow it, he has been vocal about this previously. It’s bloody expensive and the upside is not guaranteed… look at imm/immp, msb/meso and most recently Bno now bnox…
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
-0.004(7.55%) |
Mkt cap ! $79.62M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.3¢ | 4.9¢ | $389.2K | 7.789M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 777864 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 489173 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| SNT (ASX) Chart |